Donna Cotterill
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 2%
- Long-Term Effects of COVID-19
- Intracerebral and Subarachnoid Hemorrhage Research
Papers in
-
- Atrial Fibrillation Management and Outcomes 9
-
- Liver Diseases and Immunity 3
- Journals
- The Lancet (8 papers)EP Europace (3 papers)European Journal of Internal Medicine (2 papers)BMC Medicine (2 papers)Nature Communications (2 papers)
- Partner nations
- United KingdomSerbiaDenmark
In The Last Decade
Donna Cotterill
34 papers receiving 3.1k citations
Donna Cotterill's Hit Papers
Peers
Comparison fields: 5 of 115
- Infectious Diseases 971
- Neurology 558
- Hepatology 279
- Internal Medicine 111
- Applied Microbiology and Biotechnology 51
Countries citing papers authored by Donna Cotterill
This map shows the geographic impact of Donna Cotterill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Cotterill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Cotterill more than expected).
Fields of papers citing papers by Donna Cotterill
This network shows the impact of papers produced by Donna Cotterill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Cotterill. The network helps show where Donna Cotterill may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | 2015 | 220 | |
| 6 | 2018 | 214 | |
| 7 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 8 | 2018 | 189 | |
| 9 | 2019 | 153 | |
| 10 | 2017 | 135 | |
| 11 | 2018 | 125 | |
| 12 | 2017 | 108 | |
| 13 | 2023 | 83 | |
| 14 | 2019 | 68 | |
| 15 | 2022 | 60 | |
| 16 | 2022 | 51 | |
| 17 | 2021 | 47 | |
| 18 | 2016 | 46 | |
| 19 | 2021 | 41 | |
| 20 | 2022 | 31 |
About Donna Cotterill
Donna Cotterill is a scholar working on Cardiology and Cardiovascular Medicine, Hepatology, Infectious Diseases, Neurology and Epidemiology, having authored 34 papers that have together received 3.2k indexed citations. Recurring topics across this work include Atrial Fibrillation Management and Outcomes (9 papers), Liver Diseases and Immunity (3 papers), SARS-CoV-2 and COVID-19 Research (3 papers), COVID-19 Clinical Research Studies (1 paper), Patient Safety and Medication Errors (1 paper), Global Health and Surgery (1 paper), Intracerebral and Subarachnoid Hemorrhage Research (1 paper) and Hemodynamic Monitoring and Therapy (1 paper). The work is most often cited by research in Infectious Diseases (971 citations), Neurology (558 citations), Hepatology (279 citations), Internal Medicine (111 citations) and Applied Microbiology and Biotechnology (51 citations). Donna Cotterill has collaborated with scholars based in United Kingdom, Serbia and Denmark. Their work appears in journals such as The Lancet, EP Europace, European Journal of Internal Medicine, BMC Medicine and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.